FDA to Review DPP-4 Inhibitor Saxagliptin for Increased Heart Failure Risk Diabetes In Control SAVOR (Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus) trial showed a 27% increase in hospitalizations for heart failure among patients receiving saxagliptin as opposed to placebo.... Advertisement. Dipeptidyl ... |
